Foghorn Therapeutics Inc.
NASDAQ:FHTXBiotechnology
+$0.10 today
- Market cap
- $107.33M
- Beta
- 2.89
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$1.08
Volume 0.53M
Average 0.15M
FHTX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Foghorn Therapeutics Inc.NASDAQ: FHTX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 45.7% from a year ago
Cash & equivalents stood at $88.91M at the end of Q1 FY2026, up 45.7% from a year earlier and up 9.9% from the prior quarter. Over 3 fiscal years it compounded at +15.7% a year.
Context
- Cash & equivalents amounted to 40.0% of total assets at the end of Q1 FY2026, up 16.4 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +45.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 80.88M USD
- Year-over-year change
- +45.8%
- 4-year CAGR
- -5.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 80.88M | +45.8% |
| FY2024 | 2024-12-31 | 55.45M | -31.0% |
| FY2023 | 2023-12-31 | 80.34M | +53.9% |
| FY2022 | 2022-12-31 | 52.21M | -48.4% |
| FY2021 | 2021-12-31 | 101.14M | — |
Cash & Equivalents vs competitors
How FHTX compares with its peers on the latest reported figures
- FHTX's Mar 2026 cash & equivalents of $88.91M is the 3rd highest of the 11 companies compared; the peer median is $47.93M.
- Its year-over-year change of +45.7% is the highest of 11, against a peer median of -12.7%.
- Cash & equivalents amounts to 40.0% of total assets for FHTX, versus a peer median of 18.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ZURAZura Bio Limited | Mar 2026 | $225.59M | +32.3% | +311.8% | 98.7% |
| Mar 2026 | $211.38M | -2.6% | -16.2% | 86.1% | |
| Mar 2026 | $88.91M | +45.7% | +15.7% | 40.0% | |
| Mar 2026 | $76.44M | +12.7% | +26.0% | 22.8% | |
| Mar 2026 | $54.03M | -51.7% | -14.3% | 12.5% | |
| Mar 2026 | $48.54M | -22.8% | -30.4% | 43.9% | |
| Mar 2026 | $47.32M | +31.9% | +21.0% | 0.0% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $36.63M | -43.4% | +505.2% | 34.0% |
| Mar 2026 | $34.93M | -42.0% | -9.8% | 11.1% | |
| Mar 2026 | $31.12M | +32.9% | +3.7% | 13.2% | |
| Mar 2026 | $7.24M | -43.3% | -55.9% | 11.3% | |
| Peer median (excluding FHTX) | $47.93M | -12.7% | -3.0% | 18.0% | |
Competitors are the stored peer set for FHTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 101.14M | 52.21M | 80.34M | 55.45M | 80.88M |
| Short-term Investments | 53.15M | 293.58M | 153.72M | 188.29M | 78.02M |
| Net Receivables | 300M | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 5.6M | 6.12M | 5.85M | 4.34M |
| Total Current Assets | 459.56M | 351.4M | 240.18M | 249.6M | 163.24M |
| Property, Plant & Equipment (Net) | 56.08M | 49.4M | 42.91M | 32.61M | 32.86M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 4.13M | 4.09M | 2.82M | 1.78M | 2M |
| Total Non-current Assets | 60.21M | 53.48M | 45.74M | 34.38M | 34.87M |
| Total Assets | 519.77M | 404.88M | 285.92M | 283.98M | 198.1M |
| Account Payables | 3.82M | 5.41M | 6.26M | 3.79M | 4.27M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 674K | 0 | 0 |
| Deferred Revenue | 28.32M | 32.82M | 34.55M | 45.61M | 43.19M |
| Other Current Liabilities | 5.99M | 5.06M | 4.38M | 4.74M | 6.32M |
| Total Current Liabilities | 48.69M | 55.21M | 58.44M | 66.99M | 59.74M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 322.73M | 304M | 268.12M | 234.46M | 205.96M |
| Other Non-current Liabilities | 143K | 29K | 0 | 0 | 556K |
| Total Non-current Liabilities | 374.21M | 349.57M | 304.67M | 262.52M | 246.87M |
| Total Liabilities | 422.9M | 404.77M | 363.11M | 329.51M | 306.6M |
| Common Stock | 4K | 4K | 4K | 6K | 6K |
| Retained Earnings | (264.26M) | (373.14M) | (471.56M) | (558.18M) | (632.47M) |
| Accumulated OCI | (10K) | (3.99M) | (826K) | 135K | 24K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 96.87M | 112K | (77.19M) | (45.53M) | (108.5M) |
| Total Debt | 58.33M | 51.51M | 45.07M | 37.13M | 41.27M |
| Net Debt | (42.8M) | (707K) | (35.26M) | (18.32M) | (39.61M) |
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Intrinsic Alpha fair value
Locked
Current Price
$1.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.